Sodium Picosulfate
Sodium picosulfate is a stimulant laxative prodrug that is hydrolyzed by colonic bacteria to the active diphenol, which stimulates intestinal mucosa to increase peristalsis and fluid secretion, used for bowel preparation before colonoscopy and for the treatment of chronic constipation and inflammatory bowel disease. Unlike many osmotic laxatives, it acts locally in the colon and has minimal systemic absorption. It is commonly used in split-dose bowel preparation regimens in combination with magnesium citrate.
Peso Molecular
481,4000 g/mol
TPSA
163,00 Ų
Áreas Terapêuticas
Mecanismo de Ação
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Estrutura 2D
Cite this structure
Embed this structure
SMILES
O=S(=O)([O-])Oc1ccc(C(c2ccc(OS(=O)(=O)[O-])cc2)c2ccccn2)cc1.[Na+].[Na+]
InChI
InChI=1S/C18H15NO8S2.2Na/c20-28(21,22)26-15-8-4-13(5-9-15)18(17-3-1-2-12-19-17)14-6-10-16(11-7-14)27-29(23,24)25;;/h1-12,18H,(H,20,21,22)(H,23,24,25);;/q;2*+1/p-2
Molecular Formula
C18H13NNa2O8S2
HBD / HBA
- / 9
Ligações Rotacionáveis
5
Átomos Pesados
31
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
Sodium picosulfate is a stimulant laxative prodrug that is hydrolyzed by colonic bacteria to the active diphenol, which stimulates intestinal mucosa to increase peristalsis and fluid secretion, used for bowel preparation before colonoscopy and for the treatment of chronic constipation and inflammatory bowel disease. Unlike many osmotic laxatives, it acts locally in the colon and has minimal systemic absorption. It is commonly used in split-dose bowel preparation regimens in combination with magnesium citrate.
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Yes, Sodium Picosulfate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1697768. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 68654. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="sodium-picosulfate"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/sodium-picosulfate/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/sodium-picosulfate/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/sodium-picosulfate/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="sodium-picosulfate"></drugfyi-drug>